Growth Hormone Study in Adults With Prader-Willi Syndroom

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Feb 2023 The protocol has been amended to change the study design from randomized, cross-over, double-blind to observational, cohort. Timepoint for primary end-point has been increased from 27 to 36 months. The 2 treatment arms have been replaced by 1 cohort and planned enrollment decreased from 50 to 25. Minimum age limit has been decreased from 30 years to 18 years. Australia is removed from locations.
15 Feb 2023 Planned number of patients changed from 50 to 25.
15 Feb 2023 Planned End Date changed from 1 Jan 2024 to 1 Oct 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com